In vitro human skin permeation of endoxifen: Potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast

Breast Cancer: Targets and Therapy

Volumn 3, Issue , 2011, Pages 61-70

  Lee, Oukseub ^a   Ivancic, David ^a   Chatterton, Robert T ^a   Rademaker, Alfred W ^a   Khan, Seema A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer prevention; Endoxifen; Human skin; Oleic acid; Transdermal

Indexed keywords

EID: 84872769788     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S20821     Document Type: Article

References (28)

1. Jordan VC. Chemoprevention of breast cancer with selective oestrogenreceptor modulators. Nat Rev Cancer. 2007;7(1):46-53.
2. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296-300.
3. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312-9318.
4. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113-121.
5. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 2009;69(5):1722-1727.
6. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18): 1371-1388.
7. Mauvais-Javis P, Baudot N, Castaigne D, Banzet P, Kuttenn F. trans- 4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res. 1986;46(3): 1521-1525.
8. Pujol H, Girault J, Rouanet P, et al. Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue. Cancer Chemother Pharmacol. 1995;36(6):493-498.
9. Rouanet P, Linares-Cruz G, Dravet F, et al. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen. J Clin Oncol. 2005;23(13): 2980-2987.
10. Bronaugh RL, Stewart RF. Methods for in vitro percutaneous absorption studies. VI: preparation of the barrier layer. J Pharm Sci. 1986;75(5): 487-491.
11. Mansel R, Goyal A, Nestour EL, Masini-Eteve V, O'Connell K. A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women. Breast Cancer Res Treat. 2007; 106(3):389-397.
12. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy- N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005;55(5):471-478.
13. Lim YC, Li L, Desta Z, et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther. 2006;318(2):503-512.
14. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56(5):603-618.
15. Kim DD, Kim JL, Chien YW. Mutual hairless rat skin permeationenhancing effect of ethanol/water system and oleic acid. J Pharm Sci. 1996;85(11):1191-1195.
16. Kim MJ, Doh HJ, Choi MK, et al. Skin permeation enhancement of diclofenac by fatty acids. Drug Deliv. 2008;15(6):373-379.
17. Goodman M, Barry BW. Action of penetration enhancers on human skin as assessed by the permeation of model drugs 5-fluorouracil and estradiol. I. Infinite dose technique. J Invest Dermatol. 1988;91(4):323-327.
18. Fang JY, Hwang TL, Leu YL. Effect of enhancers and retarders on percutaneous absorption of flurbiprofen from hydrogels. Int J Pharm. 2003;250(2):313-325.
19. Yu B, Dong CY, So PT, Blankschtein D, Langer R. In vitro visualization and quantification of oleic acid induced changes in transdermal transport using two-photon fluorescence microscopy. J Invest Dermatol. 2001;117(1):16-25.
20. Ogiso T, Paku T, Iwaki M, Tanino T. Percutaneous penetration of fluorescein isothiocyanate-dextrans and the mechanism for enhancement effect of enhancers on the intercellular penetration. Biol Pharm Bull. 1995;18(11):1566-1571.
21. Cosman F, Baz-Hecht M, Cushman M, et al. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomizedcontrolled study and review of the literature. Thromb Res. 2005;116(1): 1-13.
22. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336):817-824.
23. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ. Estrogen receptor expression in benign breast epithelium and breast cancer risk [see comments]. J Natl Cancer Inst. 1998;90(1):37-42.
24. Ricketts D, Turnbull L, Ryall G, et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res. 1991;51: 1817-1822.
25. Ackerman AB, Kessler G, Gyorfi T, Tsou HC, Gottlieb GJ. Contrary view: the breast is not an organ per se, but a distinctive region of skin and subcutaneous tissue. Am J Dermatopathol. 2007;29(2): 211-218.
26. Povoski SP, Olsen JO, Young DC, et al. Prospective randomized trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol. 2006;13(2):10-11.
27. Klimberg VS, Rubio IT, Henry R, Cowan C, Colvert M, Korourian S. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg. 1999;229(6):860-864.
28. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 1991;51(18):4837-4844.